

Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10

JASVINDER A. SINGH, WILL J. TAYLOR, LEE S. SIMON, PUJA P. KHANNA, LISA K. STAMP, FIONA M. McQUEEN, TUHINA NEOGI, ANGELO L. GAFFO, MICHAEL A. BECKER, PATRICIA A. MacDONALD, OMAR DABBOUS, VIBEKE STRAND, NICOLA D. DALBETH, DANIEL ALETAHA, N. LAWRENCE EDWARDS, and H. RALPH SCHUMACHER Jr

ABSTRACT. *Objective.* To summarize the endorsement of measures of patient-reported outcome (PRO) domains in chronic gout at the 2010 Outcome Measures in Rheumatology Meeting (OMERACT 10).

Methods. During the OMERACT 10 gout workshop, validation data were presented for key PRO domains including pain [pain by visual analog scale (VAS)], patient global (patient global VAS), activity limitation [Health Assessment Questionnaire-Disability Index (HAQ-DI)], and a disease-specific measure, the Gout Assessment Questionnaire version 2.0 (GAQ v2.0). Data were presented on all 3 aspects of the OMERACT filters of truth, discrimination, and feasibility. One PRO, health-related quality of life measurement with the Medical Outcomes Study Short-form 36 (SF-36), was previously endorsed at OMERACT 9.

Results. One measure for each of the 3 PRO of pain, patient global, and activity limitation was endorsed by > 70% of the OMERACT delegates to have appropriate validation data. Specifically, pain measurement by VAS was endorsed by 85%, patient global assessment by VAS by 73%, and activity limitation by HAQ-DI by 71%. GAQ v2.0 received 30% vote and was not endorsed due to several concerns including low internal consistency and lack of familiarity with the measure. More validation studies are needed for this measure.

Conclusion. With the endorsement of one measure each for pain, patient global, SF-36, and activity limitation, all 4 PRO for chronic gout have been endorsed. Future validation studies are needed for the disease-specific measure, GAQ v2.0. Validation for PRO for acute gout will be the focus of the next validation exercise for the OMERACT gout group. (J Rheumatol 2011;38:1452–7; doi:10.3899/jrheum.110271)

Key Indexing Terms:

PATIENT-REPORTED OUTCOMES
PATIENT GLOBAL

CHRONIC GOUT

VALIDATION

PAIN

FUNCTIONAL LIMITATION

From the Medicine Service, Birmingham Veterans Affairs (VA) Medical Center and Division of Rheumatology, Department of Medicine and Division of Epidemiology, University of Birmingham; Center for Surgical Medical Acute Care Research and Transitions, Birmingham VA Medical Center, Birmingham, AL; Departments of Health Sciences Research and Orthopedic Surgery, Mayo Clinic School of Medicine, Rochester, MN, USA; Department of Medicine, University of Otago, Wellington, New Zealand; SDG LLC, Cambridge, MA; Division of Rheumatology, David Geffen School Of Medicine, University of California, Los Angeles, CA, USA; Department of Medicine, University of Otago, Christchurch; Department of Molecular Medicine and Pathology, Faculty of Medicine and Health Sciences, University of Auckland, Auckland, New Zealand; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA; Rheumatology Section, University of Chicago, Chicago, IL; Takeda Global Research and Development Center Inc.; Takeda Pharmaceuticals International Inc., Deerfield, IL; Stanford University, Palo Alto, CA, USA; Department of Medicine, University of Auckland, Auckland, New Zealand; Division of Rheumatology, Medical University, Vienna, Austria; Department of Medicine, University of Florida, Gainesville, FL; and Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, USA.

Supported by a National Institutes of Health (NIH) Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research) to Dr. Singh, and by resources and facilities at the Birmingham VA Medical Center, Alabama, USA. Dr. Neogi was supported by awards from the NIH K23 (AR0557127) and P60 AR047785. Dr. Khanna was supported by research grants from the NIH/NIAMS (UO1 AR057936) and an American College of Rheumatology REF Clinical Investigator Award. Data were obtained from Savient Pharmaceuticals and

Takeda Global Research and Development. Dr. Singh has received speaker honoraria from Abbott; research and travel grants from Allergan, Takeda, Savient, Wyeth and Amgen; and consultant fees from Savient, URL pharmaceuticals, and Novartis. Ms MacDonald is an employee of Takeda Global Research and Development. Dr. Dabbous is an employee of Takeda Pharmaceuticals International Inc. Dr. Schumacher has received consulting fees from Takeda, Savient, Regeneron, Novartis, and Pfizer. Dr. Becker has been a consultant for Takeda, Savient, BioCryst, URL/Pharma, Ardea, and Regeneron. Dr. Strand served as a consultant to Savient and Takeda Pharmaceuticals. Dr. Edwards has received consultant fees from Takeda and Savient. Views expressed in this article are the authors' and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.

J.A. Singh, MD, MPH, Associate Professor of Medicine, Birmingham VA Medical Center and Division of Rheumatology, Department of Medicine and Division of Epidemiology, University of Birmingham; Center for Surgical Medical Acute Care Research and Transitions, Birmingham VA Medical Center; Departments of Health Sciences Research and Orthopedic Surgery, Mayo Clinic School of Medicine; W.J. Taylor, PhD, MBChB, FRACP, Associate Professor of Medicine, Department of Medicine, University of Otago; L.S. Simon, MD, SDG LLC; P.P. Khanna, MD, Instructor of Medicine, Division of Rheumatology, David Geffen School of Medicine, University of California; L.K. Stamp, MBChB, MD, Associate Professor of Medicine; F.M. McQueen, MB, ChB, MD, Professor of Medicine, Department of Molecular Medicine and Pathology, Faculty of Medicine and Health Sciences, University of Auckland; T. Neogi, MD, MPH, Assistant Professor of Medicine; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine; A.L. Gaffo, MD, MSc, Assistant Professor of Medicine,

Birmingham VA Medical Center and Division of Rheumatology, Department of Medicine and Division of Epidemiology, University of Birmingham; M.A. Becker, MD, Professor Emeritus of Medicine, Rheumatology Section, University of Chicago; P.A. MacDonald, BSN, NP, Takeda Global Research and Development Center Inc.; O. Dabbous, MD, Takeda Pharmaceuticals International Inc.; V. Strand, MD, Adjunct Professor of Medicine, Stanford University; N.D. Dalbeth, MD, FRACP, Associate Professor of Medicine, Department of Medicine, University of Auckland; D. Aletaha, MD, MSc, Division of Rheumatology, Medical University; N.L. Edwards, MD, Professor of Medicine, Department of Medicine, University of Florida; H.R. Schumacher Jr, MD, Professor of Medicine, Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA.

Address correspondence to Dr. J.A. Singh, University of Alabama, Faculty Office Tower 805B, 510 20th Street S, Birmingham, AL 35294. E-mail: jasvinder.md@gmail.com, jasvinder.singh@va.gov

Patient-reported outcomes (PRO) are important to patients with musculoskeletal conditions just as they are to the assessment of the impact of disease and treatment of other chronic conditions. Various regulatory agencies including the US Food and Drug Administration (FDA)¹ recognize PRO as important outcomes in the assessment of new drugs; several new biologics approved for treatment of rheumatoid arthritis (RA) have an approved PRO label claim. Many initiatives such as the Patient-Reported Outcomes Measurement Information System (PROMIS) have helped to focus on PRO as important indicators of health-related quality of life (HRQOL) in chronic diseases and outcomes that matter to the patient². This is a paradigm shift from the longstanding emphasis on end-organ damage or failure (renal failure, myocardial infarction, stroke, etc.) and death as relevant outcomes of chronic diseases.

Gout is a potentially progressive and debilitating chronic inflammatory arthritis associated with pain, disability, reduction in HRQOL and ultimately in productivity, as well as morbidity^{3,4,5,6,7,8,9}. At the OMERACT 9 Meeting in 2008, outcome domains were validated for chronic gout^{10,11} and included an inner circle of mandatory domains with validated instruments for their measurement and an outer circle of desirable domains. Patients were integral to this discussion, as in other OMERACT activities. The inner circle included these PRO: pain, patient global, HRQOL by Medical Outcomes Study Short-form Survey 36 (SF-36), and activity limitation (Figure 1). The efforts of the OMERACT gout group over the last 2 years have focused on validation of remaining PRO domains in patients with chronic gout. This article summarizes progress in validation of measures for these PRO domains: pain by visual analog scale (VAS), patient global by VAS, Health Assessment Questionnaire (measuring activity limitations), and Gout Assessment Questionnaire (GAQ), a disease-specific measure of activity limitation and HRQOL. Further, we summarize data presented at the gout workshop at OMERACT 10 in Borneo, Malaysia, and describe the OMERACT endorsement of these measures specifying truth, discrimination, and feasibility for each measure. The detailed validation analyses of the PRO are the focus of separate articles submitted for publication, and are beyond the scope of this report.

Pain

Pain is a cardinal symptom of acute gout flare. Pain is an important feature of chronic gout as it is for other inflammatory arthritides including RA and spondyloarthropathies. The importance of pain as a feature of chronic gout is exemplified by its inclusion in the inner circle for the domains (Figure 1).

Pain measurement by VAS was endorsed by 85% of voters as meeting the OMERACT filters of truth, discrimination, and feasibility based on data presented (Table 1). Data presented in preparation for discussion and voting came from 2 replicate randomized controlled trials (RCT) of pegloticase versus placebo¹² that enrolled 225 patients with tophaceous gout, across 56 centers. PRO data from these 2 RCT were combined (as per FDA and company's agreement; note that the primary endpoint, as opposed to clinical endpoints, was separately analyzed) since the trials had the same methodology, design, duration (6 months), treatment interventions, and outcomes. Data presented were from baseline and end of the study visits. VAS pain has been used extensively, and therefore, has face and content validity; the specific question used in the studies is shown in Figure 2. Divergent validity was examined by comparing VAS pain scores across varying baseline tender and swollen joint counts, and SF-36 Physical Component Summary (PCS) and Mental Component Summary (MCS) score quartiles. For discrimination, VAS pain scores were compared between the treatment arms and placebo, and estimates of clinically important differences were presented. As a single question, VAS pain was regarded as feasible for the clinical trial setting.

Although not formally voted upon, a separate analysis was also presented for SF-36 bodily pain domain as a measure of pain. The SF-36 instrument as a measure of HRQOL has been validated in gout and endorsed at OMERACT 9. Analyses were derived from the above RCT of pegloticase¹² and 2 RCT with febuxostat^{13,14}. Assessment of the "truth" component of the OMERACT filter for this measure included an assessment of divergent validity by baseline number of tender and swollen joint counts, baseline disease duration, and presence of tophi. Discrimination included comparison of treatment arms.

During the breakouts, several important aspects were discussed. Discussants agreed with using the SF-36 bodily pain domain as a measure of pain severity in chronic gout. Discussants agreed that a numeric rating scale (NRS) could be substituted for the VAS. Discussants also commented that pain could be influenced by acute flares, as well as by other chronic pain conditions such as concomitant osteoarthritis and/or back pain or fibromyalgia.

Patient Global Assessment Scale

Patient global assessment of disease scales are commonly used in RCT and longitudinal observational studies (LOS) and often used as a gold standard to determine clinically meaningful changes. Validation data were derived from the 2 above




Figure 1. Outcome measures in chronic gout. Key domains for chronic gout as endorsed in 2008 at OMERACT 9. HRQOL: health-related quality of life.

Table 1. OMERACT voting results for the patient-reported outcome measures for chronic gout. A voting result for validation of 70% or higher is considered endorsement for a given measure.

Domain	Measure	OMERACT Voting Counting All Votes (%)	Excluding “Don’t know” Responses (%)	Comments During Breakouts
Pain	VAS pain	62/73 (85)	62/67 (91)	A numeric rating scale could substitute for VAS
	SF-36 pain	— (71) ^a	—	SF-36 endorsed during previous OMERACT; discussants comfortable using SF-36 pain as substitute for VAS
Patient Global	VAS	55/75 (73)	55/62 (89)	
Activity Limitation	HAQ-DI	54/76 (71)	54/59 (91)	
Disease specific measure	GAQ v2.0 ^b	22/74 (30)	22/40 (56)	Lack of familiarity with measure; concerns regarding validation

^a Endorsement for the entire SF-36 at OMERACT 9 (reference); ^b Only the Gout Concern Overall Scale and Unmet Need Scale were evaluated. SF-36: Medical Outcomes Study Short-Form 36; HAQ-DI: Health Assessment Questionnaire Disability Index; GAQ v2.0: Gout Assessment Questionnaire, version 2.0; VAS: visual analog scale.

pegloticase RCT¹² and were similar to those presented for pain VAS (Table 2). Patient global met OMERACT filters of truth, discrimination, and feasibility and was endorsed by 73% of voters (Table 1).

Activity Limitations

Chronic gout is associated with chronic pain and inflammation, joint deformities and/or joint destruction, and deposition of urate as tophi in joints and subcutaneous tissues. Each of these can result in activity limitations in patients with chronic gout. These can be measured by general instruments such as Katz activities of daily living (ADL)¹⁵. Another commonly used instrument in rheumatic conditions is the Health Assessment Questionnaire (HAQ)¹⁶. The disability index of

HAQ, HAQ-DI, has been used commonly in patients with RA and other rheumatic conditions¹⁷.

Data regarding HAQ-DI were derived from the pegloticase RCT¹² and a longitudinal observational study¹⁸. In the observational study, HAQ-DI scores were significantly higher in subjects with any tender and/or swollen joints (vs none) or presence versus absence of tophi, and were significantly different between patients who improved versus those with no change or deterioration¹⁸. HAQ-DI was also shown to fit a Rasch measurement model in gout patients and to correlate in expected ways with other measures of physical performance¹⁹. HAQ-DI was felt to meet the OMERACT filters of truth, discrimination, and feasibility with 71% of voters endorsing the measure.

VAS Pain: How much pain have you had because of your illness in the past week

No pain (0)_____Severe pain (100)

Patient Global: Considering all the ways that your arthritis affects you, rate how you are doing on the following scale by placing a vertical mark on the line

Very Well (0)_____Very Poor (100)

Figure 2. Measures for pain and patient global assessment used in 2 RCT of pegloticase¹².

Table 2. Validation data presented for patient reported outcomes in chronic gout.

	Truth				Discrimination		Feasibility
	Face Validity	Content Validity	Convergent/Divergent	Internal Consistency	Between Treatments	Sensitivity To Change	
VAS pain	✓	✓	✓	✓	✓	✓	✓
No. RCT	n/a	n/a	2	2	2	2	2
SF-36 pain	✓	✓	✓	✓	✓	✓	✓
No. RCT	n/a	n/a	4	4	4	4	4
Patient global	✓	✓	✓	✓	✓	✓	✓
No. RCT	n/a	n/a	2	2	2	2	2
HAQ-DI	✓	✓	✓	✓	✓	✓	✓
No. studies	n/a	n/a	2	2	2	2	2
GAQ v2.0	✓	✓	? ^a	? ^b	Not assessed	✓	? ^c
No. studies	n/a	n/a	1	1	0	1	2

^aCorrelations with SF-36 physical and mental component summary scores were low, raising issues regarding convergent validity;

^bLow for Unmet Gout Need subscale, but high for Gout Concern Overall and other subscales of the Gout Impact Section (GIS) of GAQ v2.0;

^c Feasibility has not been tested in research or clinical use settings. It has been self-administered by patients in one study, but the time to completion is 15-20 min.

VAS: visual analog scale; SF-36: Medical Outcome Study Short Form Survey 36; RCT: randomized controlled trials; HAQ-DI: Health Assessment Questionnaire Disability Index; GAQ v2.0: Gout Assessment Questionnaire version 2.0.

Disease-specific Measure: GAQ v2.0

Recently, a disease-specific instrument to measure HRQOL, impact of gout during acute attacks, unmet patient needs, and medication side effects and concerns has been developed²⁰. A revised GAQ v2.0 was redeveloped following patient focus groups to assess various aspects of gout considered important to them.

The initial validation study of GAQ v2.0 was a 3-center cross-sectional study of 300 gout patients performed in the US from 2006 to 2008, focusing on the Gout Impact Section (GIS; Table 3)²¹. GAQ v2.0 was shown to have good face and content validity. Internal consistency for the Gout Concern Overall scale was good, with unadjusted Cronbach’s alpha of 0.88 and adjusted Cronbach’s alpha 0.94. Lower internal consistency was noted for 2 subscales: Medication Side Effects (0.60 and 0.86, respectively) and Unmet Gout Need (0.65 and 0.86, respectively)¹⁷, and 0.35 in the RCT²². Test-retest reliability for the Gout Overall Concern subscale was 0.77, and for Unmet Treatment Need 0.76²¹. Construct validity showed correlation coefficients of –0.16 for Gout Concern Overall with PCS and –0.28 with MCS; for the Unmet Gout Treatment Need, respective correlation coefficients were –0.15 and –0.24²¹. The poor correlation with generic HRQOL instruments raised concerns regarding construct validity (truth). In an unpublished study, Gout Concern Overall showed sensitivity to change, with change scores for “markedly improved” much higher than for those who reported lesser or no change on a global scale²². Validation data for the Gout Impact Section (Gout Concern Overall, Unmet Gout Treatment Need) of GAQ v2.0 was thought to be acceptable by 30% of voters, thus indicating that GAQ v2.0 was not yet endorsed as a validated measure in gout.

Table 3. Gout Concern Overall and Gout Unmet Treatment Need subscales of the Gout Assessment Questionnaire v2.0. From J Rheumatology 2008;35:2406–14; copyright 2008 Takeda Global Research and Development Inc., adapted with permission.

Please answer every question. Read every question carefully and choose the best answer for you.

About How Gout Affects Your Daily Life Overall

1. Please indicate how much you agree or disagree with each of the statements below. (Mark one answer for each statement.)

	Strongly Agree	Agree	Not Certain	Disagree	Strongly Disagree
a. I am worried that I will have a gout attack within the next year.					
b. I am afraid that my gout will get worse over time.					
c. I feel anxious that my gout will interfere with my future activities.					
d. I worry that I will not be able to continue to enjoy my leisure activities as a result of my gout.					
e. I am bothered by side effects from my gout medications.					
f. I am mad or angry when I experience a gout attack.					
g. It is difficult to plan ahead for events or activities because I may have a gout attack.					
h. I feel depressed when I experience a gout attack.					
i. My current medications are effective for treating a gout attack when I have one.					
j. I miss planned or important activities when I have a gout attack.					
k. I worry about long term effects of gout medications.					
l. My current medications do not work well to prevent gout attacks from happening.					
m. I have control over my gout.					

Scales and items: Gout Concern Overall (4 items, 1 a-d); Unmet Gout Treatment Need (3 items, 1 i, l, m).

Breakout session discussions revealed several questions and problems regarding GAQ v2.0:

1. Lack of familiarity with the questionnaire — most people had not heard of it and the majority had not seen the questionnaire.
2. What does it measure? Discussants were not sure which domains it measured — activity limitations, disability, HRQOL, acute versus chronic gout impact, need, adverse events? They found the structure of the GAQ confusing — and considered only the Gout Impact Section (GIS) relevant.
3. Issues with internal consistency — Discussants expressed concerns regarding the internal consistency and construct validity of the Unmet Gout Treatment Need subscale, but felt comfortable with the Gout Concern Overall subscale.

Research Agenda

Several items are proposed for the research agenda related to PRO in gout. Pain, patient global, HRQOL, and activity limitations assessed by HAQ-DI or similar instruments are considered validated in chronic gout, and should be validated in acute gout — a focus for the next OMERACT. Several questions of the GAQ v2.0 make it a good subject for future research and validation. Other important suggestions from breakout groups include the following:

1. Items should be framed in relation to acute versus chronic gout, and functional limitation and other items should be framed specifically for gout.
2. The PROMIS network should be explored for additional measures of PRO.
3. Minimum clinically important differences should be anchored by perceived change scores rather than the change in disease status scores.

4. Further measurement of intermittent versus persistent pain, as well as impact of pain, should be considered.
5. Other PRO, such as fatigue, sleep, and social/work participation, should be explored to assess the impact of chronic as well as acute gout on the entire range of PRO.
6. In patients with chronic gout, distinction of PRO obtained during an acute flare versus between flares should be noted.

Summary and Conclusions

Of the PRO, HRQOL measurement with SF-36 previously met the OMERACT filters and was endorsed at OMERACT 9. Based on data from 5 RCT and 2 longterm observational studies, PRO measures that met the OMERACT filters of truth, discrimination, and feasibility included the following: pain and patient global assessments by VAS and activity limitations by HAQ-DI. Additionally, most voters agreed that NRS could substitute for the VAS pain scale to allow data collection over the telephone, using personal digital assistants, and mailed surveys. The disease-specific composite measure, GAQ v2.0, did not meet the OMERACT filters; more research is required for its validation. With the endorsements obtained at OMERACT 9 and OMERACT 10, the gout working group has made significant advances. All 4 PRO domains included in the inner circle of chronic gout outcomes now have at least one validated outcome measure that both meets the OMERACT filters and has been endorsed by OMERACT. These PRO measures should be used in both RCT and LOS to assess the impact of disease and treatment interventions for gout. Nevertheless, this endorsement should not be interpreted as implying that additional measures of these domains should not be considered. However, any additional measures need validation data and endorsement. An important item on the research agenda for the PRO subgroup of the gout group includes the examination of PRO measures in acute gout.

REFERENCES

1. U.S. Department of Health and Human Services. Food and Drug Administration. Guidance for Industry. Patient-Reported Outcome Measures: Use in Medical Product Development to support labeling claims. [Internet. Accessed 15 March 2011.] Rockville, Maryland; 2009. Available from: <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf>
2. NIH. PROMIS. Patient-Reported Outcomes Measurement Information System: dynamic tools to measure health outcomes from the patient perspective. [Internet. Accessed March 15, 2011.]. National Institutes of Health. Available from: <http://www.nihpromis.org/default.aspx>.
3. Halpern R, Fuldeore MJ, Mody RR, Patel PA, Mikuls TR. The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. *J Clin Rheumatol* 2009;15:3-7.
4. Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, et al. The impact of gout on work absence and productivity. *Value Health* 2007;10:231-7.
5. Krishnan E. Gout and coronary artery disease: epidemiologic clues. *Curr Rheumatol Rep* 2008;10:249-55.
6. Krishnan E, Baker JF, Furst DE, Schumacher HR. Gout and the risk of acute myocardial infarction. *Arthritis Rheum* 2006;54:2688-96.
7. Singh JA. Quality of life and quality of care for patients with gout. *Curr Rheumatol Rep* 2009;11:154-60.
8. Singh JA, Strand V. Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. *Ann Rheum Dis* 2008;67:1310-6.
9. Krishnan E, Svendsen K, Neaton JD, Grandits G, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout. *Arch Intern Med* 2008;168:1104-10.
10. Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, et al. Outcome domains for studies of acute and chronic gout. *J Rheumatol* 2009;36:2342-5.
11. Taylor WJ, Schumacher HR Jr, Singh JA, Grainger R, Dalbeth N. Assessment of outcome in clinical trials of gout: a review of current measures. *Rheumatology* 2007;46:1751-6.
12. Sundy JS, Baraf HSB, Becker MA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, et al. Efficacy and safety of intravenous pegloticase (pgl) in treatment failure gout (TFG): Results from GOUT1 And GOUT2 [abstract]. *Ann Rheum Dis* 2009;68 Suppl 3:318.
13. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. *N Engl J Med* 2005;353:2450-61.
14. Schumacher HR Jr, Becker MA, Wortmann RL, MacDonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. *Arthritis Rheum* 2008;59:1540-8.
15. Katz S, Ford A, Moskowitz R, Jackson B, Jaffe M. Studies of illness in aged: The index of ADL: A standard measure of biological and psychological function. *JAMA* 1963;185:914-9.
16. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980;23:137-45.
17. van Groen MM, Ten Klooster PM, Taal E, van de Laar MA, Glas CA. Application of the Health Assessment Questionnaire Disability Index to various rheumatic diseases. *Qual Life Res* 2010;19:1255-63.
18. Alvarez-Hernandez E, Pelaez-Ballesteros I, Vazquez-Mellado J, Teran-Estrada L, Bernard-Medina AG, Espinoza J, et al. Validation of the Health Assessment Questionnaire disability index in patients with gout. *Arthritis Rheum* 2008;59:665-9.
19. Taylor WJ, Colvine K, Gregory K, Collis J, McQueen FM, Dalbeth N. The Health Assessment Questionnaire Disability Index is a valid measure of physical function in gout. *Clin Exp Rheumatol* 2008;26:620-6.
20. Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N. Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness. *Int J Clin Pract* 2006;60:1210-7.
21. Hirsch JD, Lee SJ, Terkeltaub R, Khanna D, Singh J, Sarkin A, et al. Evaluation of an instrument assessing influence of gout on health-related quality of life. *J Rheumatol* 2008;35:2406-14.
22. Khanna D, Sarkin AJ, Khanna PP, Shieh MM, Kavanaugh AF, Terkeltaub RA, et al. Responsiveness to change and minimally important differences of the gout impact scale in a randomized controlled trial 2010. *Rheumatology* 2011 Mar 3. [Epub ahead of print]